Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Language
Publication year range
1.
Rev. bras. farmacogn ; 27(6): 729-738, Nov.-Dec. 2017. tab, graf
Article in English | LILACS | ID: biblio-898723

ABSTRACT

ABSTRACT The metabolism of ethanol occurs mainly in the liver, promoting increase of reactive oxygen species and nitrogen, leading to redox imbalance. Therefore, antioxidants can be seen as an alternative to reestablish the oxidizing/reducing equilibrium. The aim of this study was to evaluate the antioxidant and hepatoprotective effect of aqueous extract of Baccharis trimera (Less.) DC., Asteraceae, in a model of hepatotoxicity induced by ethanol. The extract was characterized and in vitro tests were conducted in HepG2 cells. It was evaluated the cells viability exposed to aqueous extract for 24 h, ability to scavenging the radical DPPH, besides the production of reactive oxygen species and nitric oxide, and the influence on the transcriptional activity of transcription factor Nrf2 (12 and 24 h) after exposure to 200 mM ethanol. The results showed that aqueous extract was non-cytotoxic in any concentration tested; moreover, it was observed a decrease in ROS and NO production, also promoting the transcriptional activity of Nrf2. In vivo, we pretreatment male rats Fisher with 600 mg/kg of aqueous extract and 1 h later 5 ml/kg of absolute ethanol was administrated. After two days of treatment, the animals were euthanized and lipid profile, hepatic and renal functions, antioxidant status and oxidative damage were evaluated. The treatment with extract improved liver function and lipid profile, reflecting the reduction of lipid microvesicules in the liver. It also promoted an increase of glutathione peroxidase activity, decrease of oxidative damage and MMP-2 activity. These results, analyzed together, suggest the hepatoprotective effect of B. trimera aqueous extract.

2.
Curr Pharm Biotechnol ; 16(1): 60-5, 2015.
Article in English | MEDLINE | ID: mdl-25395211

ABSTRACT

Recently, the inhibitor dipeptidyl peptidase-4 has been reported to be beneficial in the treatment of type 1 diabetes mellitus. For the first time, this study evaluates the effect of vildagliptin on ß -cell neogenesis and lipid homeostasis in a later phase of type 1 diabetes. In Fischer rats, diabetes was induced with alloxan. After confirmation of diabetic status, the animals received no treatment for 30 days to establish a late phase of the disease these animals. After this period, the animals were treated with vildagliptin via gavage for 30 consecutive days. Fasting blood glucose, serum insulin, lipid profile and pancreatic histology were evaluated. Treatment with vildagliptin increased serum levels of insulin, improved beta cell function and improved the lipid profile. Histological analyses revealed that this treatment increased the populations of pancreatic ß-cells in the diabetic animals. The treatment was effective in improving the mass and function of ß-cells and contributed to lipid homeostasis, in an experimental model of type 1 diabetes.


Subject(s)
Adamantane/analogs & derivatives , Diabetes Mellitus, Type 1/blood , Hypoglycemic Agents/pharmacology , Insulin-Secreting Cells/drug effects , Lipid Metabolism/drug effects , Nitriles/pharmacology , Pyrrolidines/pharmacology , Adamantane/pharmacology , Animals , Blood Glucose/analysis , Cell Proliferation/drug effects , Cholesterol/blood , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/pathology , Diabetes Mellitus, Type 1/pathology , Female , Insulin/blood , Insulin-Secreting Cells/cytology , Rats, Inbred F344 , Triglycerides/blood , Vildagliptin
3.
Exp Physiol ; 98(1): 57-66, 2013 01.
Article in English | MEDLINE | ID: mdl-22730415

ABSTRACT

Previous studies have shown that postweaning protein restriction induces changes in the sympathetic nervous system in rats, leading to alterations in cardiovascular parameters. In addition, the renin-angiotensin system is also affected in these animals. Here, we hypothesized that adjustments in the interaction between the RAS and SNS underlie the cardiovascular adaptations observed in rats fed a low-protein diet. Thus, we evaluated the alterations in the mean arterial pressure (MAP) and heart rate of Fisher rats fed a protein-deficient diet before and after systemic administration of the angiotensin-converting enzyme inhibitor enalapril and the angiotensin II (Ang II) type 1 (AT(1)) receptor antagonist losartan alone or in combination with the α(1)-adrenergic receptor antagonist prazosin. Administration of enalapril or losartan decreased the MAP only of rats under protein restriction. Prazosin injection after the infusion of losartan caused a further decrease in the MAP of malnourished rats. In contrast, only the administration of prazosin elicited a reduction in the MAP of control animals. When the sequence of administration of the antagonists was inverted, infusion of prazosin in animals fed the standard or the low-protein diet induced a reduction in the MAP that was further decreased by the subsequent injection of losartan. Importantly, in both protocols the responses of malnourished animals to losartan were markedly greater when compared with the control group. Moreover, these animals presented lower levels of circulating Ang II and a reduced responsiveness to Ang II. In contrast, the expression of AT(1) receptors in the aorta of malnourished animals was increased. Thus, our data suggest that the renin-angiotensin system is an important factor supporting blood pressure in rats fed a low-protein diet and that the sympathetic nervous system activity in these animals is under strong influence of Ang II acting via AT(1) receptors.


Subject(s)
Angiotensin II/metabolism , Arterial Pressure/drug effects , Receptor, Angiotensin, Type 1/metabolism , Angiotensin Receptor Antagonists/pharmacology , Animals , Diet, Protein-Restricted , Enalapril/pharmacology , Heart Rate/drug effects , Losartan/pharmacology , Male , Prazosin/pharmacology , Rats , Rats, Inbred F344 , Receptor, Angiotensin, Type 1/drug effects , Renin-Angiotensin System/physiology , Sympathetic Nervous System/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...